Fulton Breakefield Broenniman LLC acquired a new stake in shares of Colgate-Palmolive (NYSE:CL) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 4,004 shares of the company’s stock, valued at approximately $294,000.
Several other institutional investors have also recently bought and sold shares of CL. Envestnet Asset Management Inc. increased its position in shares of Colgate-Palmolive by 64.0% during the third quarter. Envestnet Asset Management Inc. now owns 610,308 shares of the company’s stock valued at $44,864,000 after acquiring an additional 238,190 shares in the last quarter. Atlantic Union Bankshares Corp grew its position in Colgate-Palmolive by 3.2% during the third quarter. Atlantic Union Bankshares Corp now owns 12,338 shares of the company’s stock valued at $907,000 after buying an additional 386 shares during the period. Robeco Institutional Asset Management B.V. grew its position in Colgate-Palmolive by 5.7% during the third quarter. Robeco Institutional Asset Management B.V. now owns 927,377 shares of the company’s stock valued at $68,172,000 after buying an additional 49,765 shares during the period. Comprehensive Portfolio Management LLC grew its position in Colgate-Palmolive by 5.8% during the third quarter. Comprehensive Portfolio Management LLC now owns 3,862 shares of the company’s stock valued at $284,000 after buying an additional 212 shares during the period. Finally, Nisa Investment Advisors LLC lifted its holdings in Colgate-Palmolive by 3.9% during the third quarter. Nisa Investment Advisors LLC now owns 347,577 shares of the company’s stock valued at $25,550,000 after purchasing an additional 13,020 shares in the last quarter. Institutional investors own 76.09% of the company’s stock.
In related news, CFO Henning I. Jakobsen sold 858 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $74.60, for a total transaction of $64,006.80. Following the completion of the sale, the chief financial officer now owns 39,031 shares of the company’s stock, valued at approximately $2,911,712.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman Ian M. Cook sold 17,750 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $68.30, for a total transaction of $1,212,325.00. Following the sale, the chairman now directly owns 995,075 shares of the company’s stock, valued at approximately $67,963,622.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 193,361 shares of company stock worth $13,722,098. 1.14% of the stock is owned by insiders.
Several equities analysts have issued reports on CL shares. Berenberg Bank initiated coverage on shares of Colgate-Palmolive in a report on Wednesday, October 16th. They set a “sell” rating and a $58.00 price objective on the stock. Morgan Stanley set a $71.00 price target on shares of Colgate-Palmolive and gave the company a “hold” rating in a research report on Monday, November 4th. ValuEngine cut shares of Colgate-Palmolive from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Piper Jaffray Companies began coverage on shares of Colgate-Palmolive in a report on Tuesday, August 13th. They issued an “overweight” rating for the company. Finally, Citigroup lifted their price target on shares of Colgate-Palmolive from $77.00 to $79.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 20th. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $72.57.
Shares of NYSE:CL traded down $0.24 on Friday, reaching $66.63. 3,082,162 shares of the company were exchanged, compared to its average volume of 3,535,509. The firm has a market cap of $57.34 billion, a price-to-earnings ratio of 22.43, a price-to-earnings-growth ratio of 5.24 and a beta of 0.73. Colgate-Palmolive has a 1-year low of $57.51 and a 1-year high of $76.41. The company has a 50-day moving average of $69.58 and a 200-day moving average of $71.58. The company has a current ratio of 1.03, a quick ratio of 0.25 and a debt-to-equity ratio of 43.94.
Colgate-Palmolive (NYSE:CL) last issued its quarterly earnings data on Friday, November 1st. The company reported $0.71 EPS for the quarter, beating the Zacks’ consensus estimate of $0.70 by $0.01. The firm had revenue of $3.93 billion for the quarter, compared to analysts’ expectations of $3.95 billion. Colgate-Palmolive had a net margin of 15.04% and a return on equity of 6,492.71%. The firm’s revenue was up 2.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.72 EPS. As a group, analysts forecast that Colgate-Palmolive will post 2.83 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Wednesday, October 23rd will be issued a $0.43 dividend. The ex-dividend date of this dividend is Tuesday, October 22nd. This represents a $1.72 dividend on an annualized basis and a yield of 2.58%. Colgate-Palmolive’s dividend payout ratio (DPR) is 57.91%.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.
Read More: What is a Candlestick Chart?
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.